Lantheus challenges Eli Lilly with FDA-approved Alzheimer’s tracer

Дата публикации: 17-08-2026 09:04:15

Основное содержимое страницы с новостью.

Eli Lilly has until now had the US market for tau PET imaging in Alzheimer’s disease to itself. The pharmaceutical giant is now facing competition after the FDA approved radiopharmaceutical company Lantheus’s Tauklarify.

August 17, 2026 11:04 AM

Tauklarify is a radioactive tracer injected before a PET scan, allowing deposits of tau protein in the brain to be visualised in adults with cognitive impairment who are being evaluated for Alzheimer’s disease.

The approval is based on two studies in which independent reviewers assessed PET scans from more than 500 participants.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	An experimental Alzheimer's drug shows promise targeting a different brain protein, new study shows	5	7	14-07-2026
2	An experimental Alzheimer's drug shows promise targeting a different brain protein, new study shows	0	6.02	14-07-2026
3	Phase III win for LSD‑based anxiety drug	0	10	13-08-2026
4	Valiltramiprosate lowers biomarkers in patients with Alzheimer’s	0	12.23	03-08-2026
5	‘One piece of this puzzle’: Pitt-CMU collaboration makes novel discovery about Alzheimer’s disease	0	17.69	06-08-2026
6	Lupin goes for bigger bites of innovation	0	8.88	29-03-2026
7	Saniona’s neurology collaboration advances as AstronauTx Exercises acquisition option	0	10	12-08-2026
8	Eli Lilly takes aim at illicit market for its experimental weight-loss drug	0	13.99	12-08-2026
9	Anthropic Considers Funding Offers At $900bn Valuation	0	12.22	30-04-2026
10	Framgång i fas III för LSD-baserad tablett mot ångest	0	21.11	13-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 22.5. Источник: www.magasinetpleje.dk.